Paradoxical gastrointestinal effects of interleukin-17 blockers
M Fauny, D Moulin, F d'Amico, P Netter… - Annals of the …, 2020 - ard.bmj.com
Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit
interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis …
interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis …
Monoclonal antibodies inhibiting IL-12,-23, and-17 for the treatment of psoriasis
C Jeon, S Sekhon, D Yan, L Afifi… - Human vaccines & …, 2017 - Taylor & Francis
Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of
the adult US population, characterized by well-demarcated, erythematous plaques with …
the adult US population, characterized by well-demarcated, erythematous plaques with …
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
RB Warren, K Reich, RG Langley… - British Journal of …, 2018 - academic.oup.com
DEAR EDITOR, Psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are
chronic inflammatory conditions. Effective long-term treatment may be necessary in women …
chronic inflammatory conditions. Effective long-term treatment may be necessary in women …
Anti-IL17 therapies for psoriasis
A Silfvast-Kaiser, SY Paek, A Menter - Expert Opinion on Biological …, 2019 - Taylor & Francis
ABSTRACT Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to
play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in …
play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in …
[HTML][HTML] Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data
L Quartuccio, A Zabotti, S Del Zotto, L Zanier… - Journal of Advanced …, 2019 - Elsevier
Risk of hospitalized infections under biologics among patients suffering from chronic
inflammatory autoimmune diseases such as rheumatoid arthritis (RA), ankylosing spondylitis …
inflammatory autoimmune diseases such as rheumatoid arthritis (RA), ankylosing spondylitis …
Agonist lock touched and untouched retinoic acid receptor-related orphan receptor-γt (RORγt) inverse agonists: classification based on the molecular mechanisms of …
Retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a potential drug target
for autoimmune diseases with a clear biological mechanism in the Th17/IL-17 pathway. The …
for autoimmune diseases with a clear biological mechanism in the Th17/IL-17 pathway. The …
An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor–positive myasthenia gravis patients
JA Villegas, J Van Wassenhove… - Annals of the new …, 2018 - Wiley Online Library
A chronic autoimmune disease, myasthenia gravis (MG) is characterized in 85% of patients
by antibodies directed against the acetylcholine receptor (AChR) located at the …
by antibodies directed against the acetylcholine receptor (AChR) located at the …
Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis
D Wendling, F Verhoeven, C Prati - Expert Opinion on Biological …, 2019 - Taylor & Francis
Introduction: Ankylosing spondylitis is the prototype of spondyloarthritis, a chronic
inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until …
inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until …
[HTML][HTML] Exceptional response of skin symptoms to secukinumab treatment in a patient with SAPHO syndrome: Case report and literature review
Q Ji, Q Wang, W Pan, Y Hou, X Wang, L Bian, Z Wang - Medicine, 2022 - journals.lww.com
Interventions: Due to the limited therapeutic efficacy of methotrexate and cyclosporin, we
started therapy with subcutaneous secukinumab 150 mg weekly for the first month, then 150 …
started therapy with subcutaneous secukinumab 150 mg weekly for the first month, then 150 …
[HTML][HTML] Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis
C Chelli, J Loget, C Vanhaecke, A Durlach… - Acta Dermato …, 2020 - ncbi.nlm.nih.gov
DISCUSSION Psoriasis and PsA are chronic inflammatory diseases, with a potentially high
impact on quality of life (4). Inflammatory factors, as TNFα and IL-17, are implicated in their …
impact on quality of life (4). Inflammatory factors, as TNFα and IL-17, are implicated in their …